Daniel A. Kracov
is a partner and is co-chair of the Life Sciences and Healthcare Regulatory practice. For decades, he has been one of the foremost Food and Drug Administration lawyers in the country, and his experience in critical regulatory matters has been widely recognised within the industry. His practice focuses on assisting pharmaceutical, biotechnology, medical device and diagnostic companies, including start-up companies, trade associations, and large manufacturers, negotiate challenges relating to the development, approval and marketing of FDA-regulated products. In addition to day-to-day counselling on regulatory strategies and concerns, he regularly handles product and compliance-related government and internal investigations, the development of global corporate compliance programmes, and due diligence in financings, mergers and acquisitions. He has widely recognised experience in biomedical public policy matters, including Congressional investigations and advising on FDA-related legislation.
Chambers and Partners make no representation or endorsement of the quality and services supplied
by companies or firms that may be found on this website. In no event will Chambers and Partners
be liable for any damages including, without limitation, indirect or consequential damages,
or any damages whatsoever arising from use or loss of use, data, or profits, whether in action
of contract, negligence or other tort action, arising out of or in connection with the use
of the website.